Acadia Dementia Drug News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AACR Meeting Presentations
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday)
Blueprint Medicines Corporation (NASDAQ: BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday)
Mirati Therapeutics, Inc. (NASDAQ: MRTX) and
BeiGene, Ltd. (NASDAQ: BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati s sitravatinib plus BeiGene s tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday)
Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday) ....

United States , Eli Lilly , Provention Bio Inc , Gain Therapeutics Inc , Instil Bio Inc , Auris Medical Holding Ltd , Finch Therapeutics Group Inc , Therapeutics Inc , Revance Therapeutics Inc , Pharmaceuticals Inc , Tg Therapeutics Inc , Theratechnologies Inc , Checkmate Pharmaceuticals Inc , Blueprint Medicines Corporation , Fibrogen Inc , Beigene Ltd , American Association Of Cancer Research , Biopharma Holdings Limited , International Society Of Nephrology , Mirati Therapeutics Inc , Chinook Therapeutics Inc , American Academy Of Neurology , Fortress Biotech Inc , World Congress , Cancer Research , Annual Meeting ,